Navigation Links
GenVec Regains Compliance with NASDAQ Listing Requirements
Date:5/5/2011

GAITHERSBURG, Md., May 5, 2011 /PRNewswire/ -- GenVec, Inc. (NASDAQ: GNVCD) today announced that on May 4, 2011, the Company received a letter from The NASDAQ Stock Market ("NASDAQ") advising that it had regained compliance with NASDAQ's minimum bid price listing requirements.

GenVec had received a notice of deficiency on May 12, 2010 stating that the Company was not in compliance with NASDAQ Marketplace Rules because the bid price of the Company's common stock had closed below the required minimum $1.00 per share for the previous 30 consecutive business days.

The letter received from NASDAQ on May 4, 2011 stated that GenVec's common stock had closed above the $1.00 minimum bid price for 10 consecutive business days and the Company had regained compliance with the minimum bid price listing requirement. NASDAQ advised that the matter is now closed.

About GenVec

GenVec is a biopharmaceutical company using differentiated, proprietary technologies to create superior therapeutics and vaccines. A key component of our strategy is to develop and commercialize our product candidates through collaborations. GenVec is working with leading companies and organizations such as Novartis, Merial, and the U.S. Government to support a portfolio of product programs that address the prevention and treatment of a number of significant human and animal health concerns. GenVec's development programs address therapeutic areas such as hearing loss, balance disorders, and cancer; as well as vaccines against infectious diseases including respiratory syncytial virus (RSV), herpes simplex virus type 2 (HSV-2), dengue fever, influenza, malaria, and human immunodeficiency virus (HIV). In the area of animal health we are developing vaccines against foot-and-mouth disease (FMD). Additional information about GenVec is available at www.genvec.com and in the Company's various filings with the Securities and Exchange Commission.

Investor and Media Contact:
GenVec, Inc.
Douglas J. Swirsky
(240) 632-5510
dswirsky@genvec.com


'/>"/>
SOURCE GenVec, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. GenVec Announces Registered Offering of $6 Million in Common Stock and Warrants
2. GenVec Expands Contract Supporting Malaria Vaccine Program
3. GenVec Reports Second Quarter 2009 Financial Results
4. GenVec Receives an Approximately $2.5 Million Grant to Support Novel Cell Line Development
5. GenVec Announces Registered Offering of $6 Million in Common Stock and Warrants
6. GenVec Announces Third Quarter 2009 Results Conference Call
7. GenVec Reports Third Quarter 2009 Financial Results
8. Merriman Curhan Ford Acted as Placement Agent in GenVecs $28 Million Registered Offering
9. GenVec to Present at the 13th Annual BIO CEO & Investor Conference
10. GenVec To Host Fourth Quarter and Year-End 2010 Earnings Call and Webcast
11. GenVec, Inc. Announces Effectiveness of Reverse Stock Split
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... NEW YORK , Feb. 23, ... , a leading digital health company, and ... of telemedicine and remote patient monitoring, announce they ... reimbursements.  DN Telehealth maximizes collaboration ... real-time, extending consultations beyond a physical clinical setting ...
(Date:2/23/2017)... JOSE, Calif. , Feb. 23, 2017 /PRNewswire/ ... exclusive license for two key immunotherapy technologies from ... first technology provides a method to monitor a ... such as PD-L1 and CTLA-4.  The second license ... if a patient is likely to have an ...
(Date:2/23/2017)... ... February 23, 2017 , ... Brain Sentinel, ... begin marketing the SPEAC® System, the Brain Sentinel® Seizure Monitoring and Alerting System. ... healthcare facilities during periods of rest. A lightweight, non-invasive monitor is placed on ...
(Date:2/23/2017)... ... February 23, 2017 , ... The Greater Gift ... new partnership with Compass Research . GGI's mission is to advance global health ... a child in need in honor of each clinical trial volunteer. The vision of ...
Breaking Biology Technology:
(Date:2/8/2017)... , Feb. 7, 2017 The biometrics ... by the confluence of organizations, desires to better ... knowledge-based systems (password and challenge questions), biometrics is ... government systems. The market is driven by use ... between consumer and enterprise uses cases, with consumer-facing ...
(Date:2/7/2017)... BEACH, New York , February 7, 2017 /PRNewswire/ ... known as ID Global Solutions Corporation [OTC: IDGS], ("Ipsidy" ... identity management and electronic transaction processing services, is pleased ... reorganization of the Company. Effective January 31, ... of the Board of Directors, CEO and President.  An ...
(Date:2/2/2017)... Feb. 2, 2017   TapImmune, Inc. ... company specializing in the development of innovative peptide ... of cancer and metastatic disease, announced today it ... manufacturing of a second clinical lot of TPIV ... receptor alpha. The manufactured vaccine product will be ...
Breaking Biology News(10 mins):